Vericel Announces Preliminary Fourth-Quarter and Full-Year 2022 Financial Results and Accelerated Launch Timeline for MACI Arthroscopic Program
January 10, 2023 07:55 ET
|
Vericel Corporation
Full-Year Total Revenue Expected to be Approximately $164 to $165 Million MACI Full-Year Revenue Expected to be at the High End of Guidance Range, with Fourth Quarter Revenue Growth of Approximately...
Vericel to Present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023
January 04, 2023 08:34 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick...
Vericel Announces FDA Approval of NexoBrid for the Treatment of Severe Thermal Burns in Adults
December 29, 2022 13:45 ET
|
Vericel Corporation
Potential to become the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns Label supported by robust clinical data demonstrating...
Vericel to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference
November 10, 2022 09:00 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that...
Vericel Reports Third Quarter 2022 Financial Results
November 09, 2022 07:55 ET
|
Vericel Corporation
Total Net Product Revenue of $38.6 Million MACI Net Revenue Increased 30% to $31.0 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Vericel...
Vericel to Report Third-Quarter 2022 Financial Results on November 9, 2022
October 26, 2022 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it...
Vericel to Present at the Ladenburg Thalmann Healthcare Conference
September 22, 2022 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that...
Vericel to Present at the Morgan Stanley Global Healthcare and H.C. Wainwright Global Investment Conferences
September 06, 2022 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that...
Vericel Reports Second Quarter 2022 Financial Results
August 03, 2022 07:55 ET
|
Vericel Corporation
Second Quarter Total Net Revenue of $37.0 Million MACI Net Revenue of $28.6 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) --...
Vericel Announces Publication of Positive Results from Retrospective Study by the Burn and Reconstructive Centers of America (BRCA) of Patients with Large Posterior Trunk Burns Treated with Epicel
July 21, 2022 16:05 ET
|
Vericel Corporation
Data published in the Journal of Burn Care & Research show 83% of patients with posterior burns (mean total body surface area of 56%) had successful engraftment of Epicel after one or two...